{
  "Disease activity (follow up: 6 months; assessed with: DAS 28-ESR)": {
    "No of studies": [
      "4"
    ],
    "Study design": "observational studies",
    "Risk of bias": "not serious",
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "serious",
      "a"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to 2nd TNFi": "390",
      "Switch to IL-6 inhibitor": "147"
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 1.3 lower (1.63 lower to 0.97 lower)"
    },
    "Certainty": " VERY LOW",
    "Importance": "CRITICAL"
  },
  "Low disease activity (follow up: 6 months; assessed with: DAS28-ESR <3.2)": {
    "No of studies": [
      "4"
    ],
    "Study design": "observational studies",
    "Risk of bias": "not serious",
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": "not serious",
    "Other considerations": "none",
    "No of patients": {
      "Switch to 2nd TNFi": "43/103 (41.7%)",
      "Switch to IL-6 inhibitor": "29/44 (65.9%)"
    },
    "Effect": {
      "Relative (95% CI)": "RR 0.63 (0.46 to 0.87)",
      "Absolute (95% CI)": "244 fewer per 1,000 (from 356 fewer to 86 fewer)"
    },
    "Certainty": "  LOW",
    "Importance": "IMPORTANT"
  },
  "Pain (follow up: 6 months; assessed with: VAS 100)": {
    "No of studies": [
      "4"
    ],
    "Study design": "observational studies",
    "Risk of bias": "not serious",
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": "not serious",
    "Other considerations": "none",
    "No of patients": {
      "Switch to 2nd TNFi": "185",
      "Switch to IL-6 inhibitor": "74"
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 1.1 lower (7.52 lower to 5.32 higher)"
    },
    "Certainty": "  LOW",
    "Importance": "IMPORTANT"
  },
  "Disability (follow up: 6 months; assessed with: HAQ-DI)": {
    "No of studies": [
      "4"
    ],
    "Study design": "observational studies",
    "Risk of bias": "not serious",
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "serious",
      "a"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to 2nd TNFi": "185",
      "Switch to IL-6 inhibitor": "74"
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 0.2 lower (0.4 lower to 0)"
    },
    "Certainty": " VERY LOW",
    "Importance": "IMPORTANT"
  },
  "Withdrawal due to adverse events (follow up: 1 year)": {
    "No of studies": [
      "4"
    ],
    "Study design": "observational studies",
    "Risk of bias": "not serious",
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": "not serious",
    "Other considerations": "none",
    "No of patients": {
      "Switch to 2nd TNFi": "49/217 (22.6%)",
      "Switch to IL-6 inhibitor": "19/35 (54.3%)"
    },
    "Effect": {
      "Relative (95% CI)": "RR 0.42 (0.28 to 0.62)",
      "Absolute (95% CI)": "315 fewer per 1,000 (from 391 fewer to 206 fewer)"
    },
    "Certainty": "  LOW",
    "Importance": "IMPORTANT"
  },
  "Withdrawal due to lack of efficacy (follow up: 6 months)": {
    "No of studies": [
      "4"
    ],
    "Study design": "observational studies",
    "Risk of bias": "not serious",
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": "not serious",
    "Other considerations": "none",
    "No of patients": {
      "Switch to 2nd TNFi": "137/217 (63.1%)",
      "Switch to IL-6 inhibitor": "11/35 (31.4%)"
    },
    "Effect": {
      "Relative (95% CI)": "RR 2.01 (1.22 to 3.31)",
      "Absolute (95% CI)": "317 more per 1,000 (from 69 more to 726 more)"
    },
    "Certainty": "  LOW",
    "Importance": "IMPORTANT"
  }
}